Articles related to ATRIAL FIBRILLATION (AFIB)

In the OPTION trial, LAAC demonstrated a 56% reduction in bleeding events compared to oral anticoagulation while maintaining equivalent stroke prevention in post-ablation patients.

Recent data shows a significant increase in pulmonary vein isolation procedures for atrial fibrillation among older adults, with concurrent decreases in complication and hospitalization rates.

Digoxin’s narrow therapeutic window and individual patient variability necessitate careful monitoring and consideration in clinical practice.

In patients with both cirrhosis and atrial fibrillation, apixaban initiation was associated with lower rates of major bleeding compared to rivaroxaban or warfarin, without compromising thromboembolic protection.

Recent advancements in atrial fibrillation management emphasize the benefits of maintaining sinus rhythm through techniques like catheter ablation, which has been associated with reduced cardiovascular complications and better overall patient outcomes.

In the complex landscape of post-cardiac surgery care, the incidence of new-onset PCSAF presents a significant challenge, necessitating a judicious approach to anticoagulation to prevent thromboembolic events while minimizing bleeding risks.